Deutsche Biotech Innovativ AG
Deutsche Biotech Innovativ AG: Deutsche Biotech Innovativ AG launches capital increase and offers shares to the public for the first time
DGAP-News: Deutsche Biotech Innovativ AG / Key word(s): Capital Increase CORPORATE NEWS Deutsche Biotech Innovativ AG launches capital increase and offers shares to the public for the first time – Public offer of up to 596,440 shares at a price of 33.50 euro per share – Issue proceeds of up to 20 million euro to provide financing especially for the continued clinical development of the project pipeline until the first trade sale or until the project is out-licensed – Aiming to be listed in the Entry Standard segment of the Frankfurt Stock Exchange Hennigsdorf, 9 October 2015 – A “Virtual Biotech” business model, an experienced management team with a proven track record and a pipeline which includes a drug candidate for a life-threatening but yet unaddressed medical condition. These are the key arguments of the investment proposal that Deutsche Biotech Innovativ AG (“DBI”; ISIN DE000A0Z25L1), a medical biotech company based in Hennigsdorf near Berlin, is making to investors on the occasion of its planned capital increase. For the first time, the new DBI shares are also offered in the context of an initial public offering (“IPO”). The corresponding securities prospectus has been published on the DBI website, after its approval by the German Federal Financial Authority (BaFin). “We are an experienced team that, following the enormous success of B.R.A.H.M.S. AG, has once again founded a new company with a very promising product pipeline. Our most exciting project is currently the development of a therapy for sepsis, or blood poisoning, the second leading cause of death worldwide, for which no approved drug is available so far,” explains Dr Bernd Wegener, the CEO of Deutsche Biotech Innovativ AG. Significant increase of free float “For us, this transaction is like a first initial public offering. As major shareholders, my management colleagues and I have financed DBI almost entirely with our own funds and we will invest another one million euros during this capital increase. The aim, however, is to open the company to external investors, in order to fully finance the development of our entire product pipeline until the first intended exit in 2018,” explains Dr Bernd Wegener. “Virtual Biotech” with unique target identification process DBI AG has an extensive network which enables access to comprehensive blood databases. These databases lay the foundation for the screening for novel drug targets in patients’ blood. From the very beginning, the starting and target point for the development of a new therapy are carefully chosen in terms of its clinical relevance. This approach is expected to increase the probability of success regarding the drug’s effectiveness in humans. Aiming for a first pipeline exit in 2018 The pre-clinical and clinical trials, which already are largely concretely planned and partially funded, are entirely carried out by project companies in which DBI AG holds a stake. Using the funds from the capital increase, DBI AG’s shares in these project companies will be increased: The shares in AdrenoMed AG will be increased to 50 per cent plus one share, in Oncoprevent GmbH to 95 per cent and in My Life Diagnostics GmbH to 75 per cent. Current research report and prospectus available The BaFin-approved prospectus is also available on the website:
About Deutsche Biotech Innovativ AG Both members of DBI’s Management Board, Dr Bernd Wegener and Dr. Andreas Bergmann, have many years of experience in the biotechnology field. Both were founders and part of the management team of B.R.A.H.M.S. AG, a highly successful biotechnology company specialized in blood biomarkers. It was sold in 2009 for around 330 million euro. Dr. Bernd Wegener is also a member of the Executive Board of the Association of the German Pharmaceutical Industry (Bundesverband der Pharmazeutischen Industrie). For more information, please contact: Deutsche Biotech Innovativ AG Kirchhoff Consult AG DISCLAIMER This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in the United States of America (the “United States”), Australia, Canada or Japan or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to in this announcement will not be and have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements under the U.S. Securities Act. Subject to certain exceptions, the securities referred to in this announcement may not be offered or sold in Australia, Canada or Japan, or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. The offer and sale of the securities referred to in this announcement has not been and will not be registered under the U.S. Securities Act or under the applicable securities laws of Australia, Canada or Japan. There will be no public offer of the securities in the United States. The public offer in Germany will solely be made by means of and on the basis of a securities prospectus published on 8 October 2015. The securities prospectus is available free of charge at the Company’s website under http://www.dbi-ag.de/investoren-presse/kapitalerhoehung-2015/ and at the headquarters of DBI AG in Hennigsdorf. 2015-10-09 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
401389 2015-10-09 |